GlaxoSmithKline
has signed a deal to manufacture cut-price HIV drugs in China in a sign that the UK group is rebuilding its presence there after a corruption scandal that badly damaged its reputation.
Under the agreement between ViiV Healthcare, the HIV unit of GSK, and Shanghai-based Desano Pharmaceuticals, the Chinese group will produce the active ingredient for its Dolutegravir, or Tivicay, medicine to widen access to HIV drugs in China and other developing countries at “competitive” prices.
您已閱讀23%（497字），剩餘77%（1689字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。